Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 2/20 | 0.42 |
| ▸ | CCR1 | P32246 | 2/20 | 0.40 |
| ▸ | CCR5 | P51681 | 2/20 | 0.40 |
| ▸ | CCR8 | P51685 | 2/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CCNB2 | O95067 | 3/20 | 0.35 |
| ▸ | CDK1 | P06493 | 3/20 | 0.35 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.35 |
| ▸ | GSK3A | P49840 | 3/20 | 0.35 |
| ▸ | GSK3B | P49841 | 3/20 | 0.35 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.35 |
| ▸ | CDK5R1 | Q15078 | 3/20 | 0.35 |
| ▸ | CCNB3 | Q8WWL7 | 3/20 | 0.35 |
| ▸ | NOS3 | P29474 | 2/20 | 0.34 |
| ▸ | NOS2 | P35228 | 2/20 | 0.34 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.34 |
| ▸ | PRKCI | P41743 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1058944 | 0.82 | CCNB2 (0.38) | PARP1ADORA3CCNB2CDK1CCNB1 | |
| SCHEMBL29487153 | 0.80 | PARP1 (0.45) | PARP1ADORA3CCNB2CDK1CCNB1 | |
| SCHEMBL12778304 | 0.80 | CCR1 (0.38) | CCR1CCR5CCR8L3MBTL1CCNB2 | |
| SCHEMBL8558723 | 0.80 | PSMD14 (0.38) | CCR1CCR5CCR8L3MBTL1CCNB2 | |
| SCHEMBL20449743 | 0.80 | DAO (0.42) | PARP1ADORA3CCNB2CDK1CCNB1 | |
| SCHEMBL4753601 | 0.80 | PARP1 (0.45) | PARP1ADORA3CCNB2CDK1CCNB1 | |
| SCHEMBL21620891 | 0.80 | NOS3 (0.41) | CCR1CCR5CCR8CCNB2CDK1 | |
| SCHEMBL21620456 | 0.80 | CCNB2 (0.40) | CCR1CCR5CCR8L3MBTL1CCNB2 | |
| SCHEMBL4362603 | 0.78 | KDM4C (0.42) | CCR1CCR5CCR8L3MBTL1CCNB2 | |
| SCHEMBL22304188 | 0.77 | GSK3A (0.36) | PARP1ADORA3CCNB2CDK1CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230271953-A1 | Novel compounds for treatment of diseases related to DUX4 expression | Facio Intellectual Property B.V. (NL) | 2023-08-31 | — | — | US | disclosed |
| WO-2020012357-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | INTEGRAL BIOSCIENCES PVT. LTD. (IN) | 2020-01-16 | — | — | WO | disclosed |
| US-20160096834-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-04-07 | — | — | US | disclosed |
| US-8586623-B2 | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | UCB PHARMA, S.A. (BE) | 2013-11-19 | — | — | US | disclosed |
| EP-1891042-B1 | 2-OXO-1-PYRROLIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR THERAPEUTIC USE ON THE CENTRAL NERVOUS SYSTEM | UCB PHARMA SA (BE) | 2013-10-02 | — | — | EP | disclosed |
| US-8518943-B2 | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | UCB PHARMA, S.A. (BE) | 2013-08-27 | — | — | US | disclosed |
| US-8507484-B2 | Preventive and/or therapeutic agent for neutrophilic inflammatory diseases | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2013-08-13 | — | — | US | disclosed |
| US-20120214815-A1 | 2-Oxo-1-Pyrrolidine Derivatives, Processes for Preparing Them and Their Uses | UCB PHARMA, S.A. (BE) | 2012-08-23 | — | — | US | disclosed |
| US-20120196866-A1 | 2-Oxo-1-Pyrrolidine Derivatives, Processes for Preparing Them and Their Uses | UCB PHARMA, S.A. (BE) | 2012-08-02 | — | — | US | disclosed |
| US-8183241-B2 | 2-oxo-1-pyrrolidine derivatives | UCB PHARMA, S.A. (BE) | 2012-05-22 | — | — | US | disclosed |
| EP-2308867-A2 | 2-oxo-1-pyrrolidine deriatives, processes for preparing them and their uses | UCB Pharma S.A. (BE) | 2011-04-13 | — | — | EP | disclosed |
| EP-2308870-A2 | 2-oxo-1-pyrrolidine deriatives, processes for preparing them and their uses | UCB Pharma S.A. (BE) | 2011-04-13 | — | — | EP | disclosed |
| US-20090312333-A1 | 2-Oxo-1-Pyrrolidine Derivatives, Processes for Preparing Them and Their Uses | UCB PHARMA, S.A. (BE) | 2009-12-17 | — | — | US | disclosed |
| US-20090156607-A1 | 2-OXO-1-PYRROLIDINE DERIVATIVES | UCB, S.A. (BE) | 2009-06-18 | — | — | US | disclosed |
| EP-1891042-A2 | 2-OXO-1-PYRROLIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR THERAPEUTIC USE ON THE CENTRAL NERVOUS SYSTEM | UCB Pharma, S.A. (BE) | 2008-02-27 | — | — | EP | disclosed |
| US-20070213361-A1 | Preventive and/or therapeutic agent for neutrophilic inflammatory diseases | KYOWA KIRIN CO., LTD. (JP) | 2007-09-13 | — | — | US | disclosed |
| WO-2006128693-A2 | 2 -OXO-I -PYRROLIDINE DERIVATIVES/ PROCESSES FOR PREPARING THEM AND THEIR THERAPEUTIC USE ON THE CENTRAL NERVOUS SYSTEM | UCB PHARMA, S.A. (BE) | 2006-12-07 | — | — | WO | disclosed |
| EP-1724271-A1 | PREVENTIVE AND/OR THERAPEUTIC AGENT FOR NEUTROPHILIC INFLAMMATION DISEASE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-11-22 | — | — | EP | disclosed |
| WO-2005082414-A2 | CONCOMITANT DRUGS OF A SULFONAMIDE AND ANOTHER THERAPEUTIC AGENT | ASTELLAS PHARMA INC. (JP) | 2005-09-09 | — | — | WO | disclosed |
| US-20050197376-A1 | Concomitant drugs | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160096834-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | BTK, SYK, LYN | PARP1 1379/4885CCR1 2353/4885CCR5 843/4885 |
| US-20230271953-A1 | Novel compounds for treatment of diseases related to DUX4 expression | UTRN, ZFX, CBX6 | PARP1 2112/4885CCR1 4108/4885CCR5 3768/4885 |
| US-20120214815-A1 | 2-Oxo-1-Pyrrolidine Derivatives, Processes for Preparing Them and Their Uses | CYP3A4, CYP1B1, CYP2D6 | PARP1 174/4885CCR1 1845/4885CCR5 1371/4885 |
| US-20090312333-A1 | 2-Oxo-1-Pyrrolidine Derivatives, Processes for Preparing Them and Their Uses | CYP3A4, CYP1B1, CYP2D6 | PARP1 174/4885CCR1 1845/4885CCR5 1371/4885 |
| US-20120196866-A1 | 2-Oxo-1-Pyrrolidine Derivatives, Processes for Preparing Them and Their Uses | CYP3A4, CYP1B1, CYP2D6 | PARP1 174/4885CCR1 1845/4885CCR5 1371/4885 |
| US-20090156607-A1 | 2-OXO-1-PYRROLIDINE DERIVATIVES | OPRD1, PPOX, CYP2D6 | PARP1 111/4885CCR1 1253/4885CCR5 928/4885 |
| US-20070213361-A1 | Preventive and/or therapeutic agent for neutrophilic inflammatory diseases | MPO, MSR1, NR4A3 | PARP1 2746/4885CCR1 19/4885CCR5 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.